Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Kidney transplantation (Tx) is the treatment of choice for end-stage chronic kidney disease, as it provides better survival, quality of life, and lower costs compared to hemodialysis (HD). However, access to this treatment and its health and economic benefits is limited due to the low organ donation rate in Chile.In 2019, a team from the University of Chile developed Kefuri, an application designed to facilitate the notification of potential organ donors (PDs) and thereby increase the donor pool. Kefuri was implemented in six high-complexity hospitals across Chile, where, after the first year of use at each center, notifications of PDs increased by an average of 94%, and effective donors by 166%.The objective of this study is to analyze the cost-effectiveness of renal replacement therapy, from the perspective of Chile’s public health system, with and without the Kefuri platform.
A three-state Markov model was designed: HD, Tx, and death. Transition probabilities and costs for each state were calculated using Chilean data from 2019–2023, adjusted for inflation and expressed in U.S. dollars as of March 31, 2024. A 5-year time horizon with monthly frequency was chosen, resulting in a 60-cycle Monte Carlo simulation.Costs were estimated through a descriptive observational study evaluating two patient cohorts — those transplanted with deceased donors and those on HD — from the initiation of renal replacement therapy in 2018 and 2019 at a hospital in Santiago, Chile. The analysis included outpatient costs plus hospitalization costs calculated using Diagnosis-Related Groups (DRGs). The death state was estimated as zero cost. Kefuri costs were based on real maintenance, development, and implementation costs and were incorporated into the Tx state.The cost-effectiveness (C-E) analysis for each alternative used QALYs (quality-adjusted life years), with utilities extracted from the literature: transplanted patients 0.71, and hemodialysis patients 0.44.
The annual average number of patients on the waiting list (WL) was 1,952. Annual Tx probabilities were 12.9% without and 21.5% with Kefuri, at an additional monthly cost of USD 79 per transplanted patient.The Markov model estimated an annual cost of USD 12,010 per patient without Kefuri versus USD 12,050 with Kefuri (+0.33%), but with 4.4 QALYs without Kefuri and 4.9 QALYs with Kefuri (+11.4% or +0.5 QALYs). The cost-effectiveness ratio (CER) was USD 2,730 per QALY without Kefuri and USD 2,459 per QALY with Kefuri. This direct C-E comparison shows that using Kefuri is 10% more cost-effective.
Although higher mortality in HD reduces its costs, Tx remains more cost-effective. Furthermore, incorporating a technology such as Kefuri, which facilitates PD notification — even without intervening in later procurement stages — further improves cost-effectiveness.These findings support efforts to develop technological tools aimed at increasing donor numbers, as they not only expand access to transplantation but also do so in a cost-effective manner.
*Work presented at the 10th Chilean Transplant Congress 2025
